|
【结 构 式】 
|
【分子编号】40980 【品名】3,5-dibromo-4-hydroxybenzaldehyde 【CA登记号】2973-77-5 |
【 分 子 式 】C7H4Br2O2 【 分 子 量 】279.91556 【元素组成】C 30.04% H 1.44% Br 57.09% O 11.43% |
合成路线1
该中间体在本合成路线中的序号：(II)The key step is the aldol condensation between 5-iodooxiindole (I) and 3,5-dibromo-4-hydroxybenzaldehyde (II) in presence of HCl in HOAc. Alternatively catalytic acid conditions may be used such as p-toluenesulfonic acid in toluene at high temperature.
| 【1】 McNutt, R.W. Jr.; Hunter, R.N. III; Jung, D.K.; Lackey, K.E.; Dickerson, S.; Harris, P.A.; Veal, J.M.; Peel, M.R. (Glaxo Group Ltd.); Benzylidene-1,3-dihydro-indol-2-one derivs. as receptor tyrosine kinase inhibitors, particularly of Raf kinases. EP 1003721; WO 9910325 . |
合成路线2
该中间体在本合成路线中的序号：(II)Also 3,5-dibromo-4-hydroxybenzaldehyde (II) is commercially available but it may also be prepared by published procedures: 1) The synthesis can be performed by treating 2,6-dibromophenol (X) with hexamethylenetetramine in acetic acid. 2) Alternatively the synthetic pathway can be the oxidation of 3,5-dibromo-4-hydroxytoluene (XI) by means of DDQ in dioxane with a small amount of water.
| 【1】 McNutt, R.W. Jr.; Hunter, R.N. III; Jung, D.K.; Lackey, K.E.; Dickerson, S.; Harris, P.A.; Veal, J.M.; Peel, M.R. (Glaxo Group Ltd.); Benzylidene-1,3-dihydro-indol-2-one derivs. as receptor tyrosine kinase inhibitors, particularly of Raf kinases. EP 1003721; WO 9910325 . |